Table 1.
Patients and tumours characteristics (n = 53)
| Smoking | 48 (90.6) |
| Family history of lung cancer | 15 (28.3) |
| Personal history of cancer | 3 (5.7) |
| Comorbidities | 17 (32.1) |
| Presentation | |
| Incidental finding | 10 (18.9) |
| Solitary pulmonary nodule | 1 (1.9) |
| Cough | 50 (40.3) |
| Dyspnoea | 18 (34.0) |
| Pain | 13 (24.5) |
| Haemoptysis | 12 (22.6) |
| Constitutional syndrome | 27 (50.9) |
| Histology | |
| Adenocarcinoma | 28 (52.8) |
| Epidermoid | 16 (30.2) |
| Undifferentiated | 5 (9.4) |
| Large cell | 3 (5.7) |
| Neuroendocrine | 1 (1.9) |
| Treatment | |
| CCT with platinum | 46 (86.8) |
| CCT and RT | 7 (13.2) |
| Stage | |
| IIB | 3 (5.7) |
| IIIA | 7 (13.2) |
| IIIB | 11 (20.8) |
| IV | 32 (60.4) |
| RECIST-1.1 diameter (mm) | 59 ± 22 (21–115) |
| Volume (cc) | 107 ± 137 (1–605) |
| Time from baseline PCT to CCT start (days) 29.37 ± 15.8 (8–82) | |
| Time from CCT start to control PCT (days) 63.9 ± 28.1 (42–138) | |
Data are given as absolute frequencies with percentages in parentheses or means ± standard deviations with ranges in parentheses. CCT Conventional chemotherapy, PCT Perfusion computed tomography, RECIST Response evaluation criteria in solid tumours, RT Radiation therapy